



Health Research Alliance

Member Organization Author Manuscript

Hypertension. Author manuscript; available in PMC 2023 September 01.

Published in final edited form as:

Hypertension. 2022 September ; 79(9): 2042–2050. doi:10.1161/HYPERTENSIONAHA.121.18765.

Address for correspondence: Elaine M. Urbina, MD, MS, Director, Preventive Cardiology, Cincinnati Children’s Hospital Medical Center, 3333 Burnet Avenue, MLC 7002, Cincinnati, OH 45229, Office: 513-636-8265, Fax: 513-636-0162, Elaine.urbina@cchmc.org.

Disclosures:

Full name	Degree	Affiliation	email	Any COI?	Disclosures
Shalayna Woodley		Cincinnati Children’s Hospital & University of Cincinnati	Shalayna.woodley@cchmc.org	Yes	AHA-moderate support
Richard Becker	MD	University of Cincinnati	BECKERRC@ucmail.uc.edu	Yes	AHA -moderate support
Stephen R Daniels	MD, PhD	Children’s Hospital Colorado	Stephen.Daniels@childrenscolorado.org	No	None
Bonita E Falkner	MD	Thomas Jefferson University	bonita.falkner@jefferson.edu	No	None
Michael Ferguson	MD	Boston Children’s Hospital	Michael.Ferguson@childrens.harvard.edu	No	None
Joseph T Flynn	MD, MS	Seattle Children’s Hospital	joseph.flynn@seattlechildrens.org	Yes	AHA -moderate support;
Jessica Haley	MD	Rady Children’s Hospital	Jhaley1@rchsd.org	No	None
Coral Hanevold	MD	Seattle Children’s Hospital	coral.hanevold@seattlechildrens.org	Yes	AHA minor support
Stephen R Hooper	PhD	University of North Carolina	stephen_hooper@med.unc.edu	Yes	AHA minor support
Julie R. Ingelfinger	MD	MassGeneral Hospital for Children at MGH Hospital	jingelfinger@nejm.org	No	None
Philip R Khoury	PhD	Cincinnati Children’s Hospital & University of Cincinnati	Phil.khoury@cchmc.org	No	None
Marc B Lande	MD, MPH	University of Rochester Medical Center	Marc_Lande@URMC.Rochester.edu	Yes	AHA minor support
Lisa J Martin	PhD	Cincinnati Children’s Hospital & University of Cincinnati	Lisa.Martin@cchmc.org	Yes	AHA minor support
Kevin Meyers	MD	Children’s Hospital of Philadelphia	meyersk@email.chop.edu	Yes	AHA minor support
Mark Mitsnefes	MD, MS	Cincinnati Children’s Hospital & University of Cincinnati	mark.mitsnefes@cchmc.org	Yes	AHA -moderate support
Bernard Rosner	PhD	Harvard University	bernard.rosner@channing.harvard.edu	Yes	AHA minor support
Joshua Samuels	MD	University of Texas Health Sciences Center	Joshua.A.Samuels@uth.tmc.edu	Yes	AHA minor support
Elaine M Urbina	MD, MS	Cincinnati Children’s Hospital & University of Cincinnati	elaine.urbina@cchmc.org	No	AHA -moderate support

Association of Blood Pressure-Related Increase in Vascular Stiffness on Other Measures of Target Organ Damage in Youth

Jessica E Haley^{*}, Shalayna A. Woodly[†], Stephen R Daniels[‡], Bonita Falkner[§], Michael Ferguson^{||}, Joseph T Flynn[#], Coral Hanevold[#], Stephen R Hooper^{**}, Julie R. Ingelfinger^{††}, Philip R Khoury[†], Marc B Lande^{‡‡}, Lisa J Martin[†], Kevin E. Meyers^{§§}, Mark Mitsnefes[†], Richard C. Becker[†], Bernard Rosner^{||||}, Joshua Samuels^{##}, Andrew Tran[†], Elaine Urbina[†]

^{*}Rady Children's Hospital San Diego, San Diego, CA

[†]Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

[‡]Children's Hospital Colorado, Denver, CO

[§]Thomas Jefferson University

^{||}Boston Children's Hospital

[#]Department of Pediatrics, University of Washington; Division of Nephrology, Seattle Children's Hospital

^{**}University of North Carolina

^{††}MassGeneral Hospital for Children at MGH Hospital

^{‡‡}University of Rochester Medical Center

^{§§}Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

^{||||}Harvard University

^{##}University of Texas Health Sciences Center, Houston, Texas

Abstract


Background: Hypertension-related increased arterial stiffness predicts development of target organ damage (TOD) and cardiovascular disease (CVD). We hypothesized that BP-related increased arterial stiffness is present in youth with elevated BP and is associated with TOD.

Methods: Participants were stratified by systolic blood pressure (SBP) into low- (L = SBP <75th percentile, N= 155), mid- (M = SBP 80th and <90th percentile, N= 88), and high-risk BP categories (H = 90th percentile, N= 139), based on age-, sex- and height-specific pediatric BP cut-points. Clinic BP, 24-hour ambulatory blood pressure monitoring (ABPM), anthropometrics and laboratory data were obtained. Arterial stiffness measures included carotid-femoral pulse wave velocity (PWV), and aortic stiffness. Left ventricular mass index (LVMI), LV systolic and diastolic function and urine albumin/creatinine were collected. ANOVA with Bonferroni correction was used to evaluate differences in CV risk factors, PWV, and cardiac function across groups. General linear models were used to examine factors associated with arterial stiffness, and to determine if arterial stiffness is associated with TOD after accounting for blood pressure.

Results: PWV increased across groups. Aortic distensibility, distensibility coefficient and compliance were greater in L than in M or H group. Significant determinants of arterial stiffness were sex, age, adiposity, BP and LDL-c. PWV and Aortic Compliance were significantly associated with TOD (systolic and diastolic cardiac function and urine albumin/creatinine ratio) after controlling for blood pressure.

Conclusions: Higher arterial stiffness is associated with elevated BP and TOD in youth emphasizing the need for primary prevention of CVD.

Graphical Abstract



Keywords

blood pressure; arterial stiffness; pediatrics; cardiac function; target organ damage; pulse wave velocity

Introduction:

Cardiovascular disease (CVD) is the world's leading cause of death.[1] Earlier onset of hypertension (HTN) is associated with greater risk for CVD,[2] which is concerning since the prevalence of elevated blood pressure (BP) in youth is near 15%.[3] Elevated BP and HTN lead to early vascular aging (EVA)[4, 5] which is associated with target organ damage (TOD) in adults[6] due to the transmission of high pressure pulsatile flow to delicate capillaries in important organs. Carotid-femoral pulse wave velocity (PWV), a measure of central arterial stiffness, is the gold standard assessment for EVA.[4] Measures of aortic stiffness and elasticity are additional measures that are also altered in pathophysiological conditions such as atherosclerosis, diabetes, and HTN.[7] Measurement of EVA is important as it is an independent predictor of CV events in adults.[8] Limited pediatric data show a similar relationship between EVA, BP and TOD but include few participants with elevated BP.[9, 10] We hypothesized that youth with elevated BP would have EVA[4] and that arterial stiffness would be related to TOD after controlling for BP.

Methods:

The study underwent institutional review board approval at each institution. Participants and their parent/guardian provided written informed assent and consent. The data are available from the corresponding author upon reasonable request.

Population:

Participants in our multi-center study to evaluate the CV effects of elevated BP included 382 youth 60% male, 63% White and 16% Hispanic, age 11–19 years, mean = 15.6 ± 1.8 years, 35% of the participants were lean, 20% were overweight and 45% were obese [11]. Participants were stratified by systolic BP (SBP) into low-risk (L = SBP <75th percentile, N= 155), mid-risk (M = SBP 80th and <90th percentile, N= 88), and high-risk BP groups (H= SBP 90th percentile, N= 139) by the Fourth Report on High BP in Children,[12] since recruitment for the study started prior to release of the American Academy of Pediatrics Clinical Practice Guidelines.[13] For analyses, BP percentiles from the 2017 CPG on BP[13] were used. Exclusion criteria included current antihypertensive drug treatment or medications affecting BP, diabetes mellitus (type 1 or 2), chronic kidney disease, congenital heart disease, or secondary hypertension. Demographic, anthropometric data, vital signs, and lab values (fasting lipid panel, fasting glucose and insulin, creatinine, uric acid, C-reactive protein [CRP], urine Na/K ratio, urine albumin/creatinine ratio [ACR]) were obtained as previously described.[14]

Clinic BP Measurement:

Cuff size was based on arm circumference.[13] Blood pressures were obtained in the right arm by auscultation using an aneroid sphygmomanometer (Mabis MedicKit5; Mabis Healthcare, Waukegan, IL). Four BP measurements were obtained at 30-second intervals on each of 2 visits, with the average of the 2nd, 3rd, 4th and 6th, 7th, 8th BP measurements used.[15]

ABPM Measurement:

Ambulatory blood pressure was measured with the OnTrak 90227 (SpaceLabs, Snoqualmie, WA) according to pediatric ABPM guidelines.[16] ABP index was calculated as the mean measured BP divided by the 95th percentile from the pediatric normative data for sex and height.[17]

Measures of CV TOD:

Cardiac images[14] were read using Cardiology Analysis System (Digisonics, Houston, TX). LV mass was calculated using the Devereaux equation[18–20] and indexed (LVMI) to $ht^{2.7}$ [21]. Systolic function was evaluated with global longitudinal strain (GLS), strain rate, time to peak longitudinal strain, time to peak longitudinal strain rate, LV ejection fraction (LVEF) and stroke volume (SV) (TOMTEC Corporation, Chicago, IL).[22] Cardiac output and systemic vascular resistance were calculated using standard formulas, with the assumption of 3 mmHg for CVP. Diastolic function was assessed using Doppler for mitral E/A and with tissue Doppler for average (septal/free wall) e'/a' and E/e' .

First morning urine albumin/creatinine (ACR) was obtained (microvascular dysfunction). [23, 24] Two individuals with extremely high ACR, had ACR set to missing.

Arterial Stiffness:

Pulse wave velocity: Carotid-femoral Pulse wave velocity (PWV) was measured using a SphygmoCor CPV (AtCor Medical, Sydney, Australia) [25, 26]. The pulse transit time (PTT) is the difference in time between the peak of the R-wave (from ECG leads) to the foot of the femoral pressure wave (obtained with a tonometer) minus the R-wave to foot of the carotid pressure wave time and PWV is distance/PTT. PWV is highly reproducible with coefficient of variation of 7%. [27]

Aortic Stiffness: Aortic stiffness was calculated using maximum diastolic and minimum systolic diameters of the ascending aorta 3–4 cm above the aortic valve in the parasternal long axis view. [28–31]

Aortic strain: $100(AoS - AoD)/AoD$

Aortic distensibility: $(2 \times Ao \text{ strain}) / (SBP - DBP)$

Beta Stiffness index: $\beta = \ln(SBP/DBP)/Ao \text{ strain}$

Distensibility coefficient: $[2 \times [(AoS - AoD)/AoD]/(SBP - DBP)]$

Aortic compliance: $\pi[(AoS^2 - AoD^2)/4(SBP - DBP)]$

Peterson Elastic Modulus[32]: $E_p = (SBP - DBP)(AoD)/(AoS - AoD)$

Statistical Analysis:

Statistical Analysis Software (SAS Institute Inc., version 9.4, Cary, North Carolina, USA) was used. Means/frequencies were obtained by BP group. Variance stabilizing procedures were employed as needed. Differences between groups were analyzed using analysis of variance with Bonferroni correction for multiple comparisons or chi square.

Independent determinants of arterial stiffness were determined from a full linear model (age, sex, race, ethnicity, waist/height ratio, LDL-C, TG/HDL ratio, HOMA-IR, Creatinine, Uric Acid, CRP, MAP, daytime Ambulatory SBP and DBP indices) reduced until all parameters remaining were significant. Additional models were constructed to determine if arterial stiffness remained a significant determinant of TOD after adjustments (same variables omitting laboratory values). Correlations were higher between arterial stiffness and BP and TOD than Cardiac Index and SVR so only arterial stiffness was modeled. Mediation analysis was performed to evaluate whether BP was mediating the relationship between arterial stiffness and TOD.

Results:

CV Risk Factors by BP group (Tables 1 and 2) showed more adverse profile at higher BP. The majority of participants were overweight (20%) or obese (45%). There were more participants with obesity in the H group compared to L group. There were no differences in lipid between groups except HDL was higher in the L compared to H group and glucose, HOMA-IR, insulin and CRP were significantly lower in the L group compared to the H group. Uric acid was lower in the L compared to the H group ($p < 0.05$). There were no significant differences found in the urine sodium/potassium ratio. Both daytime and nighttime ambulatory systolic and mean diastolic BP and indexed DBP increased across groups. There were no significant differences in systolic or diastolic dipping among groups.

PWV was higher in H than in L group ($L = 4.83 \pm 0.69$; $M = 5.08 \pm 0.76$; $H = 5.35 \pm 0.92$; $p = 0.05$) (Figure 1, Table 3) although values are within normal limits.[33] The prevalence of abnormal PWV in this entire cohort (defined as $PWV > 5.93$ m/sec from healthy lean youth) was 10%.[33] with most in H group ($L = 6.5\%$; $M = 10.2\%$; $H = 13.7\%$). H had higher percentage of abnormal PWV than L ($p = 0.039$). PWV was higher in males versus females (5.16 versus 4.95 m/sec; $P = 0.03$). Aortic distensibility, distensibility coefficient, and aortic compliance were greater in L than in M or H ($p = 0.05$). There was no significant difference between groups in aortic strain, beta stiffness index or Peterson Elastic Modulus.

Left ventricular mass index was lower in L than in H group [LVMi ($\text{g}/\text{m}^2 \cdot 7$): $L = 31.5$; $M = 33.5$; $H = 33.5$]. LVEF was higher in the L group versus M group (Table 3, all $p = 0.05$). There was no difference in other systolic function measures. E/e' was higher in the H group, (worse diastolic function). Both E/A and e'/a' trended lower (adverse) in H versus L ($p = 0.07$). The prevalence of elevated ACR was low (3.9% overall) and did not differ among groups but there was higher ACR in H vs L and M groups combined (9.3 versus 6.1 ; $p = 0.03$).

Significant determinants of PWV (Table 4) were age, waist/height ratio, MAP and ABPM nighttime diastolic index ($R^2 = 0.26$). Either clinic MAP and/or an ambulatory BP parameter was a major determinant of all measures of aortic stiffness. Male sex was a determinant for AD, $\text{Log}\beta$ stiffness index, DC and $\text{log}[\text{Peterson elastic pressure modulus}]$. LDL was associated with AS, DC, AC and $\text{log}[\text{Peterson elastic pressure modulus}]$. The amount of the variance in aortic stiffness explained by the models was low (R^2 : $AS = 0.07$, $AD = 0.12$, $\text{Log}\beta = 0.12$, $DC = 0.11$, $AC = 0.12$, $\text{log}[\text{Peterson}] = 0.09$). After adjustments, AC (Table 5) remained a determinant of E/e' and $\text{log}[\text{ACR}]$; PWV was a significant determinant of e'/a' , and T2PLS4c.

In mediation analyses BP was either not significant in a model relating arterial stiffness to TOD (time to peak strain, U_{alb}/cr ratio), or did not change the beta estimate for arterial stiffness and (e'/a') indicating no mediation by BP. However BP was significant for the model of E/e' and the beta estimate for aortic compliance was reduced substantially indicating the BP mediated the relationship between AC and E/e' (data not shown).

Discussion:

We show that youth with elevated BP had adverse CV risk profile and increased arterial stiffness and BP (clinic or ambulatory BP) is a significant predictor of arterial stiffness. In turn, arterial stiffness predicts BP-related TOD (cardiac structure and function, microvascular dysfunction). Our data are the first to show that clinic BP and out of office BP related increases in arterial stiffness may be associated with cardiac TOD in youth. Longitudinal studies are needed to determine the time course for development of elevated BP and increased arterial stiffness and to make inferences on causality.

The association between elevated BP and arterial stiffness is well documented in adults.[5, 9, 34–44] Gedikli et al. demonstrated that arterial stiffness (measured by aortic PWV and AIx) was significantly higher in a group of prehypertensive adults compared to normotensive controls.[40] Similarly, in a longitudinal study of 777 adults followed over a 25 year period, participants with either prehypertension (SBP 120–139 mmHg) or hypertension (SBP > 140 mmHg) were found to have a steeper rate of PWV increase over the study period compared to normotensive controls.[38] In addition to clinic blood pressures, elevated BP measurements on ABPM were also found to correlate with PWV.[43, 45]

Similar findings have been noted in pediatric populations.[34, 46–54] In a study of 1171 children in Switzerland (average age of 7 years), participants with elevated BP (BP 90–95th %tile) or hypertension had higher PWV compared to their normotensive peers (PWV 4.44 vs 4.56 vs 4.29).[46] In 501 Spanish youth, a graded increase in PWV was present across BP strata.[55] A recent systematic review of carotid-femoral pulse wave velocity (PWV) in youth showed that cardiometabolic risk factors were positively associated with PWV, including positive associations with BP, impaired glucose metabolism, and metabolic syndrome.[56] Our study is the largest in the U.S. to show similar increase in PWV across BP groups, suggesting that elevation in BP prior to a clinical diagnosis of HTN is associated with vascular impairment even in youth.

Few studies have evaluated ABPM data and arterial stiffness in youth. Although Stabouli et al. found a significant correlation between PWV and many ABPM parameters, including mean BP, BP load, and variability, on analysis of covariance, only weighted 24-hr SBP variability and daytime SBP variability independently predicted PWV.[47] In contrast, our study found that only clinic MAP and ABPM nighttime diastolic index were independently associated with PWV. This difference may in part be due to differences in the population studied. While Stabouli's population consisted of a random sample of younger school aged children (average age 10 years), our study population primarily consisted of adolescents with increased BMI. Our study uniquely evaluated multiple aspects of arterial stiffness in youth and demonstrated that youth with normal BP have lower arterial stiffness by aortic distensibility, distensibility coefficient and aortic compliance compared to youth with elevated BP

The association between arterial stiffness and TOD has not been well explored. A study of 338 young adults found a linear relationship between 4-chamber global longitudinal strain and lower brachial distensibility, suggesting increased arterial stiffness was associated with

subclinical decline in systolic function.[57] In a study of adolescents and young adults with systemic lupus erythematosus (SLE), Chow et al. demonstrated that carotid arterial stiffness was a significant independent determinant of LV mass, early diastolic myocardial tissue velocity, and systolic strain rate of LV free wall.[58] Another pediatric study evaluated lean, obese and diabetic youth and found LVMi to be independently associated with higher global stiffness index calculated from 5 measurements of carotid artery stiffness, augmentation index, brachial distensibility and pulse wave velocity.[10] This study further demonstrates the association between arterial stiffness and CV TOD that persists after adjustment for BP, including a reduction in subclinical systolic and diastolic function and microvascular dysfunction (increased Ualb/cr ratio). However, our mediation analyses suggest that BP does mediate the relationship between aortic compliance and diastolic function.

Perspectives

These data demonstrate that cardiovascular risk profile and arterial stiffness worsens the higher the blood pressure category in adolescents without known preexisting conditions. Our data are the first to show that clinic BP and out of office BP related increases in arterial stiffness may be associated with cardiac TOD in youth. Longitudinal studies are needed to determine the time course for development of elevated BP and increased arterial stiffness and to make inferences on causality.

Limitations:

Due to the cross-sectional design of our study, causality and overall timeline for the development of TOD in our population cannot be determined. It is possible that some participants with WCH were included in the H group, however, in our modeling we included ABPM variables to correct for this. Whether a BP related increase in arterial stiffness or other factors (obesity related insulin resistance) cause increased stiffness resulting in elevated BP cannot be determined in our cross-sectional design. Our participants were oversampled toward the higher BP distribution (> 80%ile) and this may reduce generalizability to other populations. Finally, our study utilized a tonometric device for measuring PWV which, although is the gold standard, is not equivalent to oscillometric measures of PWV[59, 60] used in other studies.

Conclusion:

Youth with elevated BP have higher arterial stiffness which is associated with other preclinical measures of TOD. Early intervention in youth with high BP should be prioritized to prevent early cardiovascular disease.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Source of Funding:

American Heart Association (AHA) grant 15SFRN2368.

Abbreviations

ABP	Ambulatory blood pressure
ABPM	Ambulatory blood pressure monitor
AC	Aortic compliance
ACR	urine albumin/creatinine ratio
ANOVA	Analysis of variance
AoD	Aortic diameter in diastole
AoS	Aortic diameter in systole
AS	Aortic stiffness
BP	Blood pressure
CDC	Center for Disease Control
CPG	Clinical practice guidelines
CVD	Cardiovascular disease
CVP	Central venous pressure
DC	Distensibility coefficient
DBP	Diastolic blood pressure
EVA	Early vascular aging
GLS	Global longitudinal strain
HTN	Hypertension
LV	Left ventricle
LVEF	Left ventricular ejection fraction
LVMi	Left ventricular mass index
LVSF	Left ventricular shortening fraction
MAP	Mean arterial pressure
NHANES	National Health and Nutrition Examination Survey
PP	Pulse pressure
PWV	Pulse wave velocity
SBP	Systolic Blood Pressure
SV	Stroke volume

TDI	Tissue doppler imaging
TOD	Target Organ Damage

References

1. Roth GA, et al. , Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019: Update From the GBD 2019 Study. *J Am Coll Cardiol*, 2020. 76(25): p. 2982–3021. [PubMed: 33309175]
2. Wang C, et al. , Association of age of onset of hypertension with cardiovascular diseases and mortality. *JACC* 2020. 75(23): p. 2921–2930. [PubMed: 32527401]
3. Jackson SL, et al. , Hypertension Among Youths - United States, 2001–2016. *MMWR Morb Mortal Wkly Rep*, 2018. 67(27): p. 758–762. [PubMed: 30001558]
4. Kucharska-Newton AM, Stoner L, and Meyer ML, Determinants of Vascular Age: An Epidemiological Perspective. *Clin Chem*, 2019. 65(1): p. 108–118. [PubMed: 30459170]
5. Benetos A, et al. , Determinants of accelerated progression of arterial stiffness in normotensive subjects and in treated hypertensive subjects over a 6-year period. *Circulation*, 2002. 105(10): p. 1202–7. [PubMed: 11889014]
6. Roman MJ, et al. , Parallel cardiac and vascular adaptation in hypertension. *Circulation*, 1992. 86(6): p. 1909–18. [PubMed: 1451262]
7. Bader H, Importance of the gerontology of elastic arteries in the development of essential hypertension. *Clin Physiol Biochem*, 1983. 1(1): p. 36–56. [PubMed: 6679476]
8. Mitchell GF, et al. , Arterial stiffness and cardiovascular events: the Framingham Heart Study. *Circulation*, 2010. 121(4): p. 505–11. [PubMed: 20083680]
9. Urbina EM, et al. , Cardiac and vascular consequences of pre-hypertension in youth. *Journal of Clinical Hypertension*, 2011. 13(5): p. 332–42. [PubMed: 21545394]
10. Urbina EM, et al. , Relationship between elevated arterial stiffness and increased left ventricular mass in adolescents and young adults. *J Pediatr*, 2011. 158(5): p. 715–21. [PubMed: 21300369]
11. Kuczmarski RJ, et al. , CDC growth charts: United States. *Adv Data*, 2000(314): p. 1–27.
12. National High Blood Pressure Education Program Working Group on High Blood Pressure in, C. and Adolescents, The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. *Pediatrics*, 2004. 114(2 Suppl 4th Report): p. 555–76. [PubMed: 15286277]
13. Flynn JT, et al. , Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents. *Pediatrics*, 2017. 140(3): p. 1–72.
14. Urbina EM, et al. , Association of Blood Pressure Level With Left Ventricular Mass in Adolescents. *Hypertension*, 2019. 74(3): p. 590–596. [PubMed: 31327264]
15. Mendizabal B, et al. , SHIP-AHOY (Study of High Blood Pressure in Pediatrics: Adult Hypertension Onset in Youth). *Hypertension*, 2018. 72(3): p. 625–631. [PubMed: 29987102]
16. Hamdani G, et al. , Prediction of Ambulatory Hypertension Based on Clinic Blood Pressure Percentile in Adolescents. *Hypertension*, 2018. 72(4): p. 955–961. [PubMed: 30354718]
17. Wuhl E, et al. , Distribution of 24-h ambulatory blood pressure in children: normalized reference values and role of body dimensions. *J Hypertens*, 2002. 20(10): p. 1995–2007. [PubMed: 12359978]
18. Devereux RB, et al. , Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. *Am J Cardiol*, 1986. 57(6): p. 450–8. [PubMed: 2936235]
19. Gottdiener JS, et al. , American Society of Echocardiography recommendations for use of echocardiography in clinical trials. *J Am Soc Echocardiogr*, 2004. 17(10): p. 1086–119. [PubMed: 15452478]
20. Lang RM, et al. , Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr*, 2015. 28(1): p. 1–39 e14. [PubMed: 25559473]

21. de Simone G, et al. , Effect of growth on variability of left ventricular mass: Assessment of allometric signals in adults and children and their capacity to predict cardiovascular risk. *Journal of the American College of Cardiology*, 1995. 25(5): p. 1056–1062. [PubMed: 7897116]
22. Dandel M, et al. , Strain and strain rate imaging by echocardiography - basic concepts and clinical applicability. *Curr Cardiol Rev*, 2009. 5(2): p. 133–48. [PubMed: 20436854]
23. Futrakul N, Sridama V, and Futrakul P, Microalbuminuria--a biomarker of renal microvascular disease. *Ren Fail*, 2009. 31(2): p. 140–3. [PubMed: 19212911]
24. Chapter 1: Definition and classification of CKD. *Kidney Int Suppl* (2011), 2013. 3(1): p. 19–62. [PubMed: 25018975]
25. Urbina EM, et al. , Noninvasive assessment of subclinical atherosclerosis in children and adolescents: recommendations for standard assessment for clinical research: a scientific statement from the American Heart Association. *Hypertension*, 2009. 54(5): p. 919–50. [PubMed: 19729599]
26. Townsend RR, et al. , Recommendations for Improving and Standardizing Vascular Research on Arterial Stiffness: A Scientific Statement From the American Heart Association. *Hypertension*, 2015. 66(3): p. 698–722. [PubMed: 26160955]
27. Urbina EM, et al. , Burden of Cardiovascular Risk Factors Over Time and Arterial Stiffness in Youth With Type 1 Diabetes Mellitus: The SEARCH for Diabetes in Youth Study. *J Am Heart Assoc*, 2019. 8(13): p. e010150. [PubMed: 31213111]
28. Nemes A, et al. , Echocardiographic evaluation and clinical implications of aortic stiffness and coronary flow reserve and their relation. *Clin Cardiol*, 2008. 31(7): p. 304–9. [PubMed: 17957740]
29. Nistri S, et al. , Aortic elasticity and size in bicuspid aortic valve syndrome. *Eur Heart J*, 2008. 29(4): p. 472–9. [PubMed: 18096569]
30. Cho JY and Kim KH, Evaluation of Arterial Stiffness by Echocardiography: Methodological Aspects. *Chonnam Med J*, 2016. 52(2): p. 101–6. [PubMed: 27231673]
31. Nichols WW ORM, McDonald's blood flow in arteries : theoretical, experimental, and clinical principles Sixth Edition ed, ed. Nichols WW ORM, Vlachopoulos C 2011, Boca Raton, FL: CRC Press. 755.
32. O'Rourke MF, et al. , Clinical applications of arterial stiffness; definitions and reference values. *Am J Hypertens*, 2002. 15(5): p. 426–44. [PubMed: 12022246]
33. Urbina EM, Kimball TR, Houry PR, Daniels SR, Dolan LM, Increased arterial stiffness is found in adolescents with obesity or obesity-related type 2 diabetes mellitus. *J Hypertens*, 2010. 28(8): p. 1692–8. [PubMed: 20647860]
34. Urbina EM, et al. , Cardiac and vascular consequences of pre-hypertension in youth. *J Clin Hypertens (Greenwich)*, 2011. 13(5): p. 332–42. [PubMed: 21545394]
35. Kudo U, et al. , Influence of obesity on blood pressure and arterial stiffness in the early teens. *Obes Res Clin Pract*, 2013. 7(3): p. e211–7. [PubMed: 23697590]
36. Whelton PK, et al. , 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Hypertension*, 2018. 71(6): p. e13–e115. [PubMed: 29133356]
37. Liang X, et al. , Determinants of pulse wave velocity trajectories from youth to young adulthood: the Georgia Stress and Heart Study. *J Hypertens*, 2019. 37(3): p. 563–571. [PubMed: 30234784]
38. Alghatrif M, et al. , Longitudinal trajectories of arterial stiffness and the role of blood pressure: the Baltimore longitudinal study of aging. *Hypertension*, 2013. 62(5): p. 934–41. [PubMed: 24001897]
39. Amar J, et al. , Arterial stiffness and cardiovascular risk factors in a population-based study. *J Hypertens*, 2001. 19(3): p. 381–7. [PubMed: 11288807]
40. Gedikli O, et al. , Effects of prehypertension on arterial stiffness and wave reflections. *Clin Exp Hypertens*, 2010. 32(2): p. 84–9. [PubMed: 20374190]
41. Cozma A, et al. , Determining Factors of Arterial Stiffness in Subjects with Metabolic Syndrome. *Metab Syndr Relat Disord*, 2018. 16(9): p. 490–496. [PubMed: 30183523]

42. Cecelja M and Chowienczyk P, Dissociation of aortic pulse wave velocity with risk factors for cardiovascular disease other than hypertension: a systematic review. *Hypertension*, 2009. 54(6): p. 1328–36. [PubMed: 19884567]
43. Rosa J, et al. , Relationship between clinical, 24-hour, average day-time and night-time blood pressure and measures of arterial stiffness in essential hypertension. *Physiol Res*, 2008. 57(2): p. 303–6. [PubMed: 18570537]
44. Coutinho T, et al. , Arterial stiffness is associated with increase in blood pressure over time in treated hypertensives. *J Am Soc Hypertens*, 2014. 8(6): p. 414–21. [PubMed: 24952654]
45. Kotsis V, et al. , Arterial stiffness and 24 h ambulatory blood pressure monitoring in young healthy volunteers: the early vascular ageing Aristotle University Thessaloniki Study (EVA-ARIS Study). *Atherosclerosis*, 2011. 219(1): p. 194–9. [PubMed: 21840525]
46. Kochli S, et al. , Obesity, High Blood Pressure, and Physical Activity Determine Vascular Phenotype in Young Children. *Hypertension*, 2019. 73(1): p. 153–161. [PubMed: 30571553]
47. Stabouli S, et al. , Arterial stiffness and SBP variability in children and adolescents. *J Hypertens*, 2015. 33(1): p. 88–95. [PubMed: 25269016]
48. Batista MS, et al. , Factors associated with arterial stiffness in children aged 9–10 years. *Rev Saude Publica*, 2015. 49: p. 23. [PubMed: 25902563]
49. Kulsum-Meccì N, et al. , Effects of Obesity and Hypertension on Pulse Wave Velocity in Children. *J Clin Hypertens (Greenwich)*, 2017. 19(3): p. 221–226. [PubMed: 27511880]
50. McCloskey K, et al. , The effect of known cardiovascular risk factors on carotid-femoral pulse wave velocity in school-aged children: a population based twin study. *J Dev Orig Health Dis*, 2014. 5(4): p. 307–13. [PubMed: 24965137]
51. Fujiwara H, et al. , Arterial stiffness in junior high school students: Longitudinal observations. *Pediatr Int*, 2018. 60(2): p. 127–135. [PubMed: 29230906]
52. Im JA, et al. , Association between brachial-ankle pulse wave velocity and cardiovascular risk factors in healthy adolescents. *J Pediatr*, 2007. 150(3): p. 247–51. [PubMed: 17307539]
53. Niboshi A, et al. , Characteristics of brachial-ankle pulse wave velocity in Japanese children. *Eur J Pediatr*, 2006. 165(9): p. 625–9. [PubMed: 16636815]
54. Tokgoz ST, et al. , The evaluation of arterial stiffness of essential hypertension and white coat hypertension in children: a case-control study. *Cardiol Young*, 2018. 28(3): p. 403–408. [PubMed: 29223189]
55. Lurbe E, et al. , Blood pressure and obesity exert independent influences on pulse wave velocity in youth. *Hypertension*, 2012. 60(2): p. 550–5. [PubMed: 22733475]
56. Stoner L, Kucharska-Newton A, and Meyer ML, Cardiometabolic Health and Carotid-Femoral Pulse Wave Velocity in Children: A Systematic Review and Meta-Regression. *J Pediatr*, 2020. 218: p. 98–105 e3. [PubMed: 31810627]
57. Mehta S, et al. , Arterial Thickness and Stiffness Are Independently Associated with Left Ventricular Strain. *J Am Soc Echocardiogr*, 2018. 31(1): p. 99–104. [PubMed: 29174337]
58. Chow PC, et al. , Relation of arterial stiffness to left ventricular structure and function in adolescents and young adults with pediatric-onset systemic lupus erythematosus. *J Rheumatol*, 2007. 34(6): p. 1345–52. [PubMed: 17477468]
59. Zinoveev A, et al. , Aortic pressure and forward and backward wave components in children, adolescents and young-adults: Agreement between brachial oscillometry, radial and carotid tonometry data and analysis of factors associated with their differences. *PLoS One*, 2019. 14(12): p. e0226709. [PubMed: 31856244]
60. Zocalo Y, et al. , Forward and Backward Aortic Components and Reflection Indexes in Children and Adolescents: Determinants and Role in High Pressure States. *Curr Hypertens Rev*, 2018. 14(2): p. 137–153. [PubMed: 29651954]

Perspectives:

In the largest multi-center study of the effect of blood pressure on target organ damage in youth, we report the effect of elevated blood pressure on arterial stiffness. We also confirm the relationship between stiffer vessels and adverse cardiac structural and functional changes.

Pathophysiological Novelty and Relevance

What is new?

- Clinic BP and out of office BP related increases in arterial stiffness may be associated with cardiac TOD in youth

What is relevant?

- Youth with elevated BP have higher arterial stiffness which is associated with other preclinical measures of TOD

Clinical/Pathophysiological Implications?

- Early intervention in youth with high BP should be prioritized to prevent early cardiovascular disease.




Figure 1.
PWV by BP group (Bonferroni corrected P 0.0001 for low < high).

Table 1.

Description of the study population (means, standard deviations or frequencies).

Characteristics	Low (L)	Mid (M)	High (H)
	N=155	N=88	N=139
Age (years)*	15.6 ± 1.6	15.9 ± 1.8	15.3 ± 1.9
Race (% non-White)	25.0	37.9	37.1
Sex (% Male)†	52.3	71.6	61.2
Height (cm)**	168.7 ± 9.1	171.8 ± 10.9	168.5 ± 9.9
Weight (kg)‡	76.7 ± 23.3	85.6 ± 29.0	84.8 ± 25.0
BMI (kg/m2)§	26.7 ± 7.0	28.7 ± 8.6	29.7 ± 7.9
BMI percentile (%)§	78.0 ± 41.5	80.6 ± 20.9	86.4 ± 20.9
Obese (%)§	36.1	46.6	54.7
Waist (cm)§	86.1 ± 18.8	89.1 ± 19.5	93.5 ± 19.7
Waist/height ratio	0.5 ± 0.1	0.5 ± 0.1	0.6 ± 0.1
Total cholesterol (mg/dl)	152.0 ± 30.1	153.8 ± 34.8	154.3 ± 33.2
LDL (mg/dl)	86.6 ± 26.9	90.7 ± 28.8	92.5 ± 28.4
HDL (mg/dl)#	47.4 ± 12.2	44.1 ± 11.5	43.3 ± 11.7
Triglycerides (mg/dl)	94.5 ± 62.2	99.4 ± 58.6	96.3 ± 48.8
Glucose (mg/dl)§	87.9 ± 8.0	89.5 ± 10.4	90.8 ± 8.2
Insulin (microIU/dl)§	17.9 ± 14.4	20.0 ± 14.4	23.8 ± 19.0
HOMA_IR§	3.98 ± 3.46	4.47 ± 3.31	5.48 ± 4.78
CRP (mg/dl)§	1.30 ± 1.69	1.39 ± 1.74	1.95 ± 2.16
Creatinine (mg/dl)**	0.72 ± 0.13	0.79 ± 0.18	0.72 ± 0.17
Uric acid (mg/dl)§	5.41 ± 1.63	5.81 ± 1.40	6.04 ± 1.52
Urine sodium/potassium ratio	4.09 ± 3.01	4.19 ± 3.16	3.99 ± 2.64

Bonferroni adjusted P 0.04 for

* H<M

† M<L

[†]L<M&H
[§]L<H
//L&M<H
#H<L
**L&H<M

BMI, body mass index; *CRP*, C-reactive protein; *DBP*, diastolic blood pressure; *HDL*, high density lipoprotein; *HR*, heart rate; *K1*, Korotkoff sound 1; *K5*, Korotkoff sound 5; *LDL*, low density lipoprotein; *MAP*, mean arterial pressure; *SBP*, systolic blood pressure.

Table 2.

Cardiovascular parameters stratified by BP group (means, standard deviations).

Characteristics	Low (L) N=155	Mid (M) N=88	High (H) N=139
K1 SBP (mmHg)*	111.5 ± 9.8	126.0 ± 5.6	132.7 ± 7.2
K4 DBP (mmHg)†	74.3 ± 13.1	82.9 ± 12.8	86.3 ± 13.4
K5 (mmHg)†	67.2 ± 9.9	73.3 ± 8.1	75.4 ± 10.5
MAP (mmHg)*	81.9 ± 8.7	90.9 ± 5.9	94.5 ± 7.6
SBP percentile (%)*	50.6 ± 27.1	86.1 ± 7.6	95.3 ± 3.3
DBP percentile (%)†	53.2 ± 29.1	69.1 ± 23.7	75.3 ± 26.0
HR (bpm)‡	72.0 ± 12.2	68.0 ± 11.6	73.6 ± 13.3
Ambulatory Daytime SBP (mmHg)*	117.9 ± 9.5	125.1 ± 9.0	130.5 ± 10.9
Ambulatory Daytime SBP Index*	0.88 ± 0.07	0.92 ± 0.07	0.97 ± 0.08
Ambulatory Nighttime SBP (mmHg)*	103.3 ± 9.2	110.0 ± 9.3	114.4 ± 10.6
Ambulatory Nighttime SBP Index*	0.88 ± 0.07	0.92 ± 0.08	0.97 ± 0.09
Ambulatory Daytime DBP (mmHg)*	69.0 ± 6.4	72.4 ± 6.8	75.0 ± 8.3
Ambulatory Daytime DBP Index*	0.84 ± 0.08	0.88 ± 0.08	0.91 ± 0.10
Ambulatory Nighttime DBP (mmHg)*	55.7 ± 5.7	58.1 ± 6.2	61.2 ± 8.6
Ambulatory Nighttime DBP Index*	0.84 ± 0.09	0.88 ± 0.10	0.92 ± 0.13
SBP dipping (%)	12.2 ± 6.1	11.9 ± 5.8	12.0 ± 5.9
DBP dipping (%)	19.0 ± 7.6	19.4 ± 7.8	18.1 ± 8.4
Cardiac Output (ml/min)§, #	3.2 ± 1.0	3.5 ± 1.3	3.9 ± 1.3
Cardiac Index (L/min/m2) , #	1.7 ± 0.5	1.8 ± 0.5	2.0 ± 0.6
Systemic Vascular Resistance, metric (dynes*sec*cm ⁻⁵) #	2190.7 ± 738.3	2221.4 ± 780.0	2115.6 ± 749.4
Systemic Vascular Resistance (Wood units) #	27.4 ± 9.2	27.8 ± 9.7	26.4 ± 9.4

Bonferroni adjusted p 0.05 for

* L<M<H

[†]L<M&L
[‡]M<H
[§]L<H
^{||}L&M<H

n is different for these parameters (L = 123, M = 78, H = 112) due to inability to make these measurements on the full cohort.

Table 3.

Stiffness Parameters & Measures of TOD Parameters stratified by BP group (means, standard deviations).

Characteristics	Low (L) N=155	Mid (M) N=88	High (H) N=139
Pulse Wave Velocity (m/sec)*	4.83 ± 0.69	5.08 ± 0.76	5.35 ± 0.92
Aortic Strain (unitless)	17.9 ± 7.9	18.1 ± 6.7	19.0 ± 7.7
Beta Stiffness index (unitless)	3.58 ± 2.30	3.60 ± 2.38	4.82 ± 11.45
Peterson Elastic Modulus (mmHg)	72.0 ± 41.5	81.5 ± 43.5	113.8 ± 237.4
Aortic Distensibility (1/mmHg)[†]	0.0084 ± 0.0039	0.0071 ± 0.0027	0.0069 ± 0.0030
Distensibility Coefficient (1/mmHg)[†]	0.02 ± 0.01	0.01 ± 0.01	0.01 ± 0.01
Aortic Compliance (mm/mmHg)[†]	0.030 ± 0.013	0.025 ± 0.011	0.023 ± 0.010
LVM Index (g/m^{2.7})*	31.5 ± 6.7	33.5 ± 6.8	33.5 ± 7.2
Shortening Fraction (%)	37.6 ± 4.4	36.7 ± 5.0	38.0 ± 5.0
Ejection Fraction (%)[‡]	58.0 ± 7.2	55.4 ± 6.7	56.3 ± 6.7
Peak Longitudinal Strain (%)[§]	-20.9 ± 3.5	-19.9 ± 3.2	-20.1 ± 3.4
Peak Longitudinal Strain Rate (/sec)	-1.03 ± 0.24	-1.02 ± 0.24	-1.03 ± 0.2
Time to peak longitudinal strain (msec)	37.2 ± 6.2	37.6 ± 6.1	38.8 ± 6.0
Time to peak longitudinal strain rate (msec)	22.9 ± 10.2	21.8 ± 9.5	22.8 ± 8.0
e'/a' ratio [§]	2.47 ± 0.79	2.38 ± 0.62	2.27 ± 0.67
E/A ratio [§]	2.35 ± 0.70	2.24 ± 0.66	2.16 ± 0.63
E/e' ratio^{//}	6.09 ± 1.38	5.88 ± 1.32	6.63 ± 1.60
Urine Albumin/Creatinine ratio	6.140 ± 7.500	6.040 ± 7.920	9.280 ± 20.250

Bonferroni adjusted P 0.05 for

* L<H

[†] M&H<L

[‡] M<L

[§] model p <0.07

^{//} L&M<H. Higher values indicate worsening arterial stiffness for the following parameters: Pulse Wave Velocity, Aortic Strain, Beta Stiffness index, Peterson Elastic Modulus. Lower values indicate worsening arterial stiffness for the following parameters: Aortic distensibility, Distensibility Coefficient, Aortic Compliance.

Table 4:

Determinants of Arterial Stiffness

	PWV	Aortic strain	Aortic distensibility	Log Beta Stiffness Index	Distensibility Coefficient	Aortic Compliance	Log Peterson elastic pressure modulus
Intercept	-0.5	24.6	0.01	1.8	0.03	0.05	3.7
Age	0.07					0.004	
Sex (male)			0.002	-0.1	0.003		-0.1
Waist/height	2.06						
LDL		-0.03			-0.00002	-0.00005	0.002
logCRP			-0.0004	0.05			
Creatinine				0.5			
Mean Arterial Pressure	0.01			-0.02		0.0002	-0.008
ABP daytime SBP index					-0.02	-0.05	1.4
ABP daytime DBP index	2.6			0.8			
ABP nighttime SBP index		16.0	-0.007				
ABP nighttime DBP index		-20.7					
R ²	0.26	0.07	0.12	0.12	0.11	0.12	0.09

Full model included: age, race, sex, waist-to-height ratio, LDL, Triglyceride, HDL, HOMA-IR, Creatinine, Urine acid, CRP, MAP, HR, Ambulatory SBP Index Daytime, Ambulatory DBP Index Daytime. All model p 0.0001 and all parameter estimates 0.05.

Table 5:

Association of Different Measures of Arterial Stiffness with Left Ventricular and Microvascular Dysfunction

	E/e'	e'/a'	Time to Peak Longitudinal strain	Log Urine Albumin/ Creatinine
Pulse Wave Velocity (femoral)		-0.05	0.91	
Aortic compliance	0.02			-13.09
Intercept	3.04	1.96	12.82	-5.54
Age	-0.14			
Sex (male)		0.08	1.83	0.23
Waist/height	2.54	-0.85		-2.22
Mean Arterial Pressure			0.08	
ABP daytime SBP index	6.89	0.48		0.81
ABP daytime DBP index	-3.04	-0.71		
Heart rate		-0.01	0.15	0.01
R²	0.2	0.26	0.17	0.11

Full model included: age, race, sex, waist-to-height ratio, HR, Ambulatory SBP Index Daytime, Ambulatory DBP Index Daytime and one of the arterial stiffness variables. All model $p < 0.0001$ and all parameter estimates > 0.05 . Increase in E/e' or decrease in e'/a' is consistent with worsening diastolic function. Increase in strain indicates worse systolic function.